Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Norethisterone Enantate→

Norethisterone Enantate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
3836-23-5
Molecular formula
C27H38O3
Molecular weight
410.6 g/mol
Drug class
Long-acting progestogen esterinjectable norethisterone prodrug
Mechanism of action
After intramuscular administration, norethisterone enantate is slowly released and hydrolysed to norethisterone, which activates progesterone receptors and suppresses ovulation, thickens cervical mucus and alters the endometrium.
Indications / reported uses
  • Long-acting progestogen-only contraception by intramuscular injection in countries where norethisterone enantate products are authorised; it is not the same as oral norethisterone indications for endometriosis or abnormal uterine bleeding

Sources: WHO — Family planning and injectable progestogens · PubMed — Norethisterone enantate contraceptive pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Norethisterone Enantate Environmental Risk Assessment (ERA) (the Norethisterone Enantate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.